Santhera Reports Submission of Marketing Authorization Application to the EMA for Puldysa (Idebenone) in Duchenne Muscular Dystrophy

 Santhera Reports Submission of Marketing Authorization Application to the EMA for Puldysa (Idebenone) in Duchenne Muscular Dystrophy

Santhera Reports Submission of Marketing Authorization Application to the EMA for Puldysa (Idebenone) in Duchenne Muscular Dystrophy

Shots:

  • The MAA submission follows the results of P-II DELPHI study, DELPHI-Extension study, P-III DELOS (1-5) study and SYROS study. The collective studies result demonstrated that Puldysa (idebenone) is showing clinical benefits & long-term efficacy in patients with DMD
  • Santhera also plans to submit NDA to the FDA following the completion of P-III SIDEROS study assessing Puldysa (Idebenone) in 266 patients with DMD administering glucocorticoid steroids from 18mos. across 60 sites including Europe, the US and Israel
  • Puldysa (Idebenone) is a chemical analog of benzoquinone and a co-factor for quinone oxidoreductase (NQO1) and has received the ODD designation in Europe, the US, Switzerland & Australia and a FT designation by the US FDA

Click here to read full press release/ article | Ref: Santhera | Image: Santhera

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post